Seaport Therapeutics debuts with $238.7M IPO, advancing two neuropsychiatric trials

Filed June 8, 2026 · Period ending March 31, 2026 · ~2 min read

Key Changes

• high

  Completed May 2026 IPO raising $238.7M net at $18/share, providing cash runway into 2029 to fund lead programs GlyphAllo (Phase 2b depression trial, topline data H1 2027) and GlyphAgo (Phase 1 anxiety/depression, Phase 2a data early 2028).

  MD&A: IPO and Cash Runway verify on EDGAR →
• high

  GlyphAllo Phase 2b BUOY-1 trial enrolling full 360-patient target for major depressive disorder without interim analysis, signaling confidence in potential registration path; topline results expected first half 2027.

  MD&A: GlyphAllo Clinical Status verify on EDGAR →
• high

  GlyphAgo Phase 1 data showed 6.8-fold bioavailability improvement and 10-fold lower variability versus unmodified agomelatine with no liver-related adverse events, validating Glyph platform's ability to improve drug pharmacokinetics.

  MD&A: GlyphAgo Phase 1 Results verify on EDGAR →